Posted by Administrator on September 30, 2015 · Leave a Comment
Yesterday, Google announced the release of a variety of new hardware including two new Nexus phones, new Chromecasts, and the Pixel C Android tablet.
Here's a breakdown of the some the items and their features:
Nexus 6P
Google's new flagship phone has a slightly smaller screen than its predecessor at 5.7 inches, metal, and about the size of an iPhone 6 Plus.
It comes with a fingerprint sensor, known as the Nexus Imprint, which can be used to unlock the phone, and a 12.3-megapixel rear camera, that uses a Sony sensor with large pixels intended for low-light shooting, as well as the options to shoot 4K video.
On the front, the phone sports an 8-megapixel camera.
As a bonus, according to Google, the phone can be charged in half the time it takes to charge an iPhone 6 Plus.
Available in white, silver, and black with an $89 two-year warranty, the phone comes both unlocked and compatible with Google's Project Fi network.
It's now available for pre-order in many countries, with the 32-gigabyte model selling for US$499, and the 64- and 128-gigabyte models, for $549 and $649, respectively.
Shipping starts in October, 2015.
Nexus 5
This phone, made by LG now comes with s 5.2-inch 1080p display. The Nexus 5 shares many features with the 6P including Nexus Imprint, USB Type-C, and the same 12.3-megapixel rear camera.
5X preorders have started, with the 16- and 32-gigabyte models selling for $379 and $429. The phone comes in white, blue, and black.
As with the Nexus 6P, shipping will start next week.
Pixel C
The Pixel C is Google's new 10.2-inch tablet, that comes with an Nvidia X1 processor, 3 gigabytes of RAM, and Android Marshmallow. Selling prices start at $499, with an optional $149 keyboard available to add on.
The tablet is shipping a little later than the phones, in time for the holidays.
Chromecast and Chromecast Audio
The second-generation Chromecast comes in a new disc shape, in your choice of red, black, or yellow. Improvements include better Wi-Fi, thanks to two additional antennas and support for 5-gigahertz connections.
Coming in the next few weeks is an updated Chromecast app for iOS and Android, which will include playback controls, cross-service voice search, and a "What's On" section for browsing content from compatible apps.
Spotify officially announced support for the Chromecast platform, along with Google revealing the Chromecast Audio, a device with RCA, 3.5mm, and optical connections instead of HDMI.
The Audio and the second-gen Chromecast have started shipping for $35 each.
Related Articles Filed under All Stories, Computing, Mobile · Tagged with android, Chromecast, google, spotify
Recent Digital Forum Threads Source: Google Rolls Out New Hardware Including New Nexus Phones and Tablet
Mylan announced the U.S. launch of Paliperidone Extended-Release Tablets 1.5 mg, 3 mg, 6 mg and 9 mg, the generic version of Janssen's Invega. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of schizophrenia in adults and adolescents (12 – 17 years of age) in addition to schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers and/or antidepressants in adults.
Drug maker Gilead Sciences announced that its investigational drug paired with the blockbuster drug Sovaldi scored high cure rates with six genotypes of the hepatitis C virus in late-phase clinical trials for treatment of the disease. The company released topline results for four international phase 3 clinical studies, dubbed ASTRAL, that tested a once-daily, fixed-dose combination of velpatasvir (VEL), an investigational drug and sofosbuvir (SOF), marketed by Gilead as Sovaldi. Velpatasvir is being developed by the company as a pangenotypic NS5A inhibitor for the treatment of chronic hepatitis C infection for patients with genotypes 1 through 6 of the virus, according to the company statement. "The ASTRAL study results demonstrate that a 12-week course of therapy with the first fixed-dose combination of two pan-genotypic compounds can provide high cure rates for pati ents with all HCV (hepatitis C virus) genotypes," said Norbert Bischofberger, PhD, Gilead's executive vice president of research and development and chief scientific officer. "We are pleased to have now brought forward our second single tablet regimen for HCV infection that complements Harvoni, our first single tablet regimen approved specifically for patients with genotype 1 infection and which could eliminate the need for HCV genotype testing. We look forward to advancing the regulatory submissions for the SOF/VEL fixed-dose combination." The primary efficacy endpoint for all four studies was for patients to achieve sustained virologic response (SVR) at 12 weeks after they completed treatment, an indication that the patient is cured because the virus is no longer detectable in the blood. The main endpoint was achieved by 98% of patients in three trials, the release states. There were 20 patients who did not meet the endpoint and of those 13 experienced virologic failure and seven were lost to follow-up and did not complete the SVR12 visit, the release states. There were a total of 1035 patients in ASTRAL trials 1, 2 and 3 who were given SOF/VEL for 12 weeks to treat hepatitis C infection, including genotypes 1 through 6. Among those patients, 21% had compensated cirrhosis and 28% had not been cured in previous hepatitis C treatment attempts, according to the release. Patients from all three studies who were given SOF/VEL had similar adverse events to those who were given placebo in the ASTRAL-1 study and two patients stopped taking the drug due to adverse events. The most common side effects were headache, fatigue and nausea, according to the release. There were nine deaths among the 18% of patients who experienced treatment-emergent serious adverse events (SAEs), the release states. Gilead said the deaths were associated with advanced liver disease, as was the majority of the (SAEs), and were not related to the study drug. In ASTRAL 4, the f ourth trial, patients with decompensated cirrhosis who were given ribavirin along with SOF/VEL for 12 weeks achieved higher SVR12 rates (94%) than those who were given SOF/VEL for either 12 or 24 weeks (83% and 86% respectively). The most common adverse events among the 264 patients in this study were fatigue, nausea and headache, the release states. Gilead's latest hepatitis C investigational drug, SOF/VEL, has been granted breakthrough therapy status by the FDA, which could help hasten the path to approval. The company said it plans to file a drug approval application with the agency and European drug authorities by the end of 2015. 
Microsoft is getting ready to bring out the best of them next month with some brilliant new devices. The tech company is on its way to announcing the new Microsoft Lumia 940, its upcoming tablet the Surface Pro 4 and the Microsoft Band 2. We finally have an official release date for these devices which is quite optimistic too.
Since this tablet is probably the highlight of the event we'll be focusing on the alleged tech specs of the device. It could arrive with Intel's new Skylake processor which improves performance tenfold, and some rumors claim that the Surface Pro 4 will have 8GB of RAM which is huge. Obviously we're expecting a very good battery life and Microsoft will surely deliver in this department given the masterpiece that is Windows 10, and given Intel's brilliant new processor. All in all we will have to wait until October to see Microsoft out its newest tablet, its newest flagship device and the Band 2.
The Kio tablet in use. Image: Ushahidi A tough flight case, ruggedised tablets, a virtually indestructible router/modem with a built-in microserver: it looks like it might be designed for mobile C&C police or military units, but the BRCK Kio Kit is made with a more benevolent aim in mind.
Posted by admin on Sep 22, 2015. Filed under Technology. You can follow any responses to this entry through the RSS 2.0. Both comments and pings are currently closed. 
AMAZON
AMAZON
AMAZON
Yes, Samsung has retained the phone app in this tablet so, should your SIM allow it, you can place calls on what will look like the biggest handset in the known world. According to reports from August, the tablet sports an 18.4-inch display and is now code named Tahoe but may launch as the Galaxy View, a name Samsung has already confirmed for an upcoming tablet.
